S114 Simvastatin improves neutrophil migratory targeting in COPD: in vitro studies supporting Statin use as a potential adjuvant therapy. (14th November 2013)

• Record Type: Journal Article
• Authors: Sadhra, CS; Purvis, T; Walton, GM; Stockley, JA; Stockley, RA; Sapey, E
• Is Part Of: Thorax. Volume 68(2013)Supplement 3
• Page Start: A59
• Page End: A60
• Publication Date: 2013-11-14
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2013-204457.121
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction: Statin use in COPD is associated with a reduction in all cause mortality, with greatest reductions seen in patients with the highest inflammatory burden. However, the mechanism for these effects is poorly understood, as statin treatment has not been found to lower systemic inflammation and in vitro studies of cellular effects use concentrations that exceed the therapeutic range. Neutrophils are key effector cells in COPD, and correlate with disease severity and inflammation. Recent in vitro studies have shown neutrophil migratory accuracy to be reduced in COPD. This is thought to contribute to the destruction of lung parenchyma and the poor responses seen in infective exacerbations. We aimed to characterise neutrophil migration in COPD and assess whether physiologically relevant concentrations of simvastatin altered neutrophil migration. Methods: Neutrophils were isolated from COPD patients and healthy smoking age-matched controls (age > 60yrs, n = 13 per group) and incubated with 1nM - 1μM Simvastatin or with a carrier control before migratory dynamics were assessed towards IL8 and fMLP using time-lapse photography. Data is expressed as means with standard deviation in parentheses. Results: COPD neutrophils displayed reduced chemotaxis (directional speed of migration) and reduced chemotactic accuracy (Chemotactic Index - a vector analysis of migratory tracks) compared to cells from healthy age-matched controls (HC) in the presence of IL-8 and f-MLP, replicating previous work. For example, Chemotactic Index: IL8; HC, 0.42CU (0.03), COPD 0.22CU (0.05), p = 0.002: fMLP; HC, 0.34CU (0.05), COPD, 0.18CU (0.03) p = 0.014). Treatment with Simvastatin significantly improved the chemotactic ability of COPD neutrophils in a dose response with greatest improvement seen at the highest concentration (e.g. Chemotaxis to IL8, Carrier control 0.8um/min (0.2), 1nM Simvastatin 1.3um/min (0.2), p = 0.04; 1uM Simvastatin 1.4um/min (0.2), p = 0.004). A similar improvement was seen in Chemotactic Accuracy (e.g. Chemotactic Index to fMLP, Carrier control 0.17CU (0.03), 1nM Simvastatin 0.26CU (0.02), p = 0.018; 1uM Simvastatin 0.31CU (0.03), p = 0.002). Conclusions: Migratory accuracy of circulating neutrophils is reduced in COPD patients compared with healthy, smoking, age-matched controls but can be restored by treatment with therapeutic concentrations of Simvastatin in vitro . Our data suggest statin therapy might be an adjuvant intervention in COPD, modulating neutrophil responses.